Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BIIB022, Taxol, Paraplatin, Taxane, Anti-IGF-1R, Cytotoxic, Mitotic Inhibitor, IGF-1R
BIIB022 With Paclitaxel and Carboplatin · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| BIIB022 in Combination with Paclitaxel and Carboplatin | EXPERIMENTAL | BIIB022 in Combination with Paclitaxel and Carboplatin |
| Sorafenib Monotherapy | EXPERIMENTAL | Sorafenib Monotherapy |
| Sorafenib with BIIB022 | EXPERIMENTAL | Sorafenib with BIIB022 |
| BIIB022 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| BIIB022 With Paclitaxel and Carboplatin | DRUG | Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin |
| BIIB022 | DRUG | IV Q3W |
| Sorafenib | DRUG | Standard dosing of Sorafenib |
Inclusion Criteria: * Age \>/= 18 years old * Treatment-naive Stage IIIB/IV Non-Small Cell Lung Cancer * ECOG Performance Status 0 or 1 Exclusion Criteria: * History of another primary cancer within 3 years * Any prior or concurrent investigational or standard therapy for treatment of NSCLC * Pri...
BIIB022 is an investigational agent studied in oncology for hepatocellular carcinoma, non-small cell lung cancer, and solid tumors. It was evaluated in Phase 1 trials, including in combination with paclitaxel and carboplatin in non-small cell lung cancer and with sorafenib in hepatocellular carcinoma. It is not an approved therapy.
BIIB022 is an anti-IGF-1R monoclonal antibody, meaning it targets insulin-like growth factor 1 receptor (IGF-1R). By binding this receptor, it is designed to interfere with IGF-1R mediated signaling in tumor cells. It was studied in relapsed or refractory solid tumors as well as in combination regimens.
BIIB022 was developed by Biogen Inc., which trades on Nasdaq under the ticker BIIB. The company sponsored the Phase 1 clinical program evaluating BIIB022 across solid tumors, non-small cell lung cancer, and hepatocellular carcinoma.
BIIB022 is in Phase 1 development. All of its recorded clinical trials were Phase 1 studies, and those trials are completed. There are no active trials of BIIB022, and the agent is not approved for any indication.
BIIB022 was studied in three completed Phase 1 trials: NCT00970580 in non-small cell lung cancer with paclitaxel and carboplatin, NCT00956436 in hepatocellular carcinoma with sorafenib, and NCT00555724 in relapsed or refractory solid tumors. These trials enrolled patients in the United States and several other countries.